<DOC>
	<DOCNO>NCT01712087</DOCNO>
	<brief_summary>This post-approval study primarily evaluate long-term safety MedStream Programmable Infusion System use combination Baclofen treatment severe spasticity . A secondary objective , assess long-term effectiveness , base observed score Ashworth Scale ( rigidity low extremity ) Spasm Scores 36-month follow-up period also describe .</brief_summary>
	<brief_title>Long-term Surveillance MedStream Programmable Infusion System</brief_title>
	<detailed_description />
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>The subject viable candidate `` de novo '' continue ( pump replacement ) therapy treatment severe spasticity intrathecal Baclofen deliver implantable programmable pump . The subject his/her Legally Authorized Representative must voluntarily provide Informed Consent participation study accordance 21 Code Federal Regulations ( CFR ) Part 50 . The subject willing comply protocolspecified followup visit requirement period 36 month implant . The subject anticipated life expectancy 24 month great . The subject must 18 year age old time MedStream implant procedure . The subject sufficient body size accommodate pump placement , opinion Investigator . The subject receive de novo replacement implant MedStream 20 mL 40 mL pump , MedStream approve catheter ( ) MedStream accessory . The Investigator intend use Baclofen pump treatment severe spasticity The subject capable selfreporting spasm frequency . Concurrent enrollment investigational device drug study complete required followup period . Subject infection and/or inflammation near pump and/or catheter implantation site ( ) within 30 day precede enrollment . Evidence fever infection within 10 day prior surgical implant procedure , opinion Investigator might impact successful pump implant . The subject know hypersensitivity/allergies contraindication Baclofen material infusion pump catheter ( ) . The subject comorbid condition could limit his/her ability participate study comply followup requirement , might impact scientific integrity study . The subject rapid degenerative neurological disease lateral sclerosis , amyotrophic lateral sclerosis ( ALS ) , rapidly progressive Multiple Sclerosis , inherit rapidly progressive leukodystrophies , Moyamoya disease , cerebral autosomal dominant arteriopathy subcortical infarct leucoencephalopathy ( CADASIL ) , thrombophilias , rapidly progressive autoimmune disorder , disorder progression underlie spinal cord central nervous system ( CNS ) disease expect progress significantly next 3 year Subject prisoner . Subject previously enrol study . Subject pregnant breastfeeding . ( Note : female child bear potential must negative pregnancy test prior enrollment study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>spasticity</keyword>
	<keyword>muscle spasticity</keyword>
	<keyword>muscle rigidity</keyword>
	<keyword>motor neuron disease</keyword>
	<keyword>hyperreflexia</keyword>
</DOC>